DRUG NAME: Sertraline

Sertraline hydrochloride is the marketed salt form. Since no alternative salts with clinically distinct properties exist, the base name “Sertraline” is used throughout this monograph. International brand name Zoloft (Pfizer) — in India, the originator brand was marketed as Daxid (Pfizer).

Therapeutic Class: Antidepressant

Subclass: Selective Serotonin Reuptake Inhibitor (SSRI)

Speciality:

Primary Speciality: Psychiatry
Also used in: Obstetrics & Gynaecology, Neurology

Schedule (India): Schedule H

Route(s): Oral (tablets, oral solution)

Biosimilar Status:
Not a biologic — biosimilar classification not applicable. Sertraline is a small-molecule synthetic naphthylamine derivative.

Formulations Available in India:

Dosage Form	Strengths Available	Notes
Film-coated tablets	25 mg, 50 mg, 100 mg	Widely available from multiple manufacturers
Tablets	150 mg	Limited brands; not universally stocked
Oral solution/concentrate	20 mg/mL	Limited availability in India; not commonly prescribed

Clinically Relevant FDCs Available in India:

FDC	Strengths	Notes
Sertraline + Clonazepam	25 mg/0.25 mg, 25 mg/0.5 mg, 50 mg/0.5 mg	Commonly prescribed in India for depression/anxiety with prominent anxiety component. ℹ️ Long-term benzodiazepine use is discouraged — FDC should be used for short-term initiation (2–4 weeks) only, then benzodiazepine should be tapered.
Sertraline + Methylcobalamin	50 mg/1500 mcg	Available from some manufacturers. Clinical rationale for the combination is weak.

⛔ Banned FDCs: No sertraline-containing FDC has been banned by CDSCO as of the most recent gazette notifications. However, prescribers should verify current CDSCO FDC status periodically.

PHARMACOKINETICS

Parameter	Value
Bioavailability (oral)	Estimated ~44% (substantial first-pass hepatic metabolism). Absolute bioavailability not precisely determined in humans.
Tmax	4.5–8.4 hours
Protein binding	~98% (primarily to albumin and alpha-1 acid glycoprotein)
Volume of distribution (Vd)	~20 L/kg (extensive tissue distribution)
Metabolism	Hepatic — extensively metabolised via multiple CYP isoenzymes: CYP2B6 (major), CYP2C19, CYP2C9, CYP2D6, and CYP3A4. Primary metabolite: N-desmethylsertraline (substantially less active — approximately 1/8th the serotonin reuptake inhibition potency of parent compound; half-life 62–104 hours). CYP inhibition profile: Moderate inhibitor of CYP2D6. Weak inhibitor of CYP1A2, CYP2C9, CYP2C19, CYP3A4. Drug transporters: Substrate of P-glycoprotein (P-gp). Not a clinically significant inhibitor or inducer of P-gp, OATP1B1/1B3, or BCRP at therapeutic doses.
Half-life (t½)	Sertraline: ~26 hours (range 22–36 hours). N-desmethylsertraline: 62–104 hours. Half-life may be prolonged in hepatic impairment. Not significantly prolonged in renal impairment.
Excretion	Urine (~40–45%) and faeces (~40–45%) — almost entirely as metabolites. <0.2% excreted unchanged in urine.
Dialysability	Not significantly removed by haemodialysis (high protein binding of 98%, large Vd). No supplemental post-dialysis dose required.
Food effect	Food increases Cmax by ~25% and slightly decreases Tmax. Clinically, this effect is minor. Can be taken with or without food. Taking with food may reduce initial GI side effects (nausea).
Onset of action	Antidepressant effect: 2–4 weeks for clinical response; maximum benefit often at 6–8 weeks. Some anxiolytic effect may be noted earlier (1–2 weeks). Initial worsening of anxiety/agitation may occur in first 1–2 weeks.
Duration of action	Once-daily dosing provides sustained therapeutic effect due to 26-hour half-life plus accumulation of long-lived metabolite. Steady state achieved in approximately 7 days.

Non-linear PK: At doses above 150 mg, metabolism may approach saturation for some CYP pathways, leading to slightly greater-than-proportional increases in plasma levels. Clinically relevant non-linearity is not significant at standard doses (50–200 mg).

Population PK Notes

Population	PK Difference
Elderly	Clearance reduced by ~40%. Plasma levels may be higher at any given dose. Start at lower dose.
Hepatic impairment	Significantly reduced clearance. AUC and Cmax increased. Half-life prolonged. Dose reduction essential.
Renal impairment	No clinically significant change (minimal renal excretion of unchanged drug).
Paediatric	Clearance per kg slightly higher in children aged 6–12 years compared to adolescents; however, standard weight-adjusted dosing is appropriate.
Pregnancy	Clearance may increase in second and third trimesters due to increased hepatic blood flow and CYP activity. Some patients may need dose increase to maintain efficacy.
Obesity	Vd may be increased. Limited specific data. Standard dosing is used.
Critical illness / ICU	Data limited. Absorption may be impaired in critically ill patients. Consider drug interactions with ICU medications.

INDICATIONS + DOSING (FOR CLINICIAN USE ONLY)

Primary Indications (Approved / Standard in India)

1. Major Depressive Disorder (MDD)

Parameter	Details
Starting dose	50 mg once daily (may start at 25 mg once daily in patients prone to GI side effects or with significant anxiety)
Titration	Increase by 25–50 mg at intervals of at least 1 week
Usual maintenance dose	50–150 mg once daily
Maximum dose	200 mg per day (single dose)
Duration	Minimum 6 months after remission of first episode. For recurrent depression: at least 2 years or indefinite, based on clinical judgment.

Mandatory Clinical Notes:

When to prefer over alternatives: Sertraline is recommended as a first-line SSRI for MDD due to its favourable balance of efficacy, tolerability, drug interaction profile (lower CYP inhibition than fluoxetine or paroxetine), and cardiac safety (supported by SADHART trial). Preferred in patients with cardiac comorbidity, elderly patients, and when a drug with moderate half-life is desired. [Evidence-based]
When NOT to use: Do not use as first-line in patients on MAOIs (14-day washout mandatory), patients with known QT prolongation on high-dose SSRIs, or patients with bipolar depression (risk of manic switch — mood stabiliser must be in place first).
NLEM India status: Sertraline is not included in NLEM India 2022. Fluoxetine (20 mg) is the listed SSRI in NLEM.
Time to expected clinical response: Initial response in 2–4 weeks. Full therapeutic benefit may take 6–8 weeks. ℹ️ Warn patient that improvement is gradual — premature discontinuation is a major cause of treatment failure.
Treatment failure criteria: No meaningful improvement in PHQ-9 or clinical assessment after 6–8 weeks at adequate dose (≥100 mg/day). Consider switching to another SSRI/SNRI, augmentation (lithium, atypical antipsychotic), or referral to psychiatrist.
Mandatory baseline investigations:
- MANDATORY: Clinical mood assessment (PHQ-9 or equivalent), suicidality risk assessment
- RECOMMENDED: Weight, blood pressure, serum sodium (especially if elderly or on diuretics), liver function tests
- OPTIONAL: ECG (if patient >60 years or has cardiac risk factors), FBC
Specialist vs primary care: Can be initiated in primary care for mild-to-moderate depression. Specialist referral recommended for: severe depression with suicidality, treatment-resistant depression, bipolar depression, comorbid substance use disorder, or when augmentation strategies are needed.
Indian guideline source: API Textbook of Medicine — Chapter on Psychiatric Disorders (Depression); Indian Psychiatric Society (IPS) Clinical Practice Guidelines for Management of Depression (2017).
⚠️ Key disease-specific safety warning: Increased suicidality risk in patients aged 18–24 years during first 4 weeks of treatment. Close monitoring mandatory. Do not prescribe large quantities of tablets to patients with suicidal risk.
Dose adjustment scenarios: Start at 25 mg in elderly, hepatic impairment, panic disorder, significant anxiety, or concurrent CYP inhibitors. May need higher doses (150–200 mg) in OCD vs MDD.

2. Obsessive-Compulsive Disorder (OCD)

Parameter	Details
Starting dose	50 mg once daily
Titration	Increase by 50 mg at intervals of at least 1 week
Usual maintenance dose	100–200 mg once daily
Maximum dose	200 mg per day
Duration	Minimum 1–2 years. Many patients require lifelong treatment.

Mandatory Clinical Notes:

When to prefer: First-line pharmacotherapy for OCD (along with fluvoxamine, fluoxetine). Recommended when CBT alone is insufficient or unavailable. [Evidence-based]
When NOT to use: Mild OCD responding to CBT alone does not require pharmacotherapy.
NLEM India status: Not in NLEM India 2022.
Time to response: 4–6 weeks for initial response. Full response may take 8–12 weeks. OCD typically requires higher SSRI doses and longer trial duration compared to MDD.
Treatment failure criteria: <25% reduction in Y-BOCS score after 12 weeks at maximum tolerated dose. Consider switching to clomipramine or augmenting with low-dose antipsychotic (risperidone, aripiprazole).
Mandatory baseline investigations: Same as MDD.
Specialist vs primary care: Specialist initiation recommended. Primary care may continue established therapy.
Indian guideline source: IPS Clinical Practice Guidelines for OCD; API Textbook.
Key safety warning: Same suicidality warning as MDD in young adults.
Dose adjustment: OCD routinely requires doses at the higher end (150–200 mg) compared to MDD. Start titration early.

3. Panic Disorder (with or without Agoraphobia)

Parameter	Details
Starting dose	⚠️ 25 mg once daily (lower starting dose is critical — standard 50 mg start can precipitate initial worsening of panic)
Titration	Increase to 50 mg after 1 week, then increase by 25–50 mg at intervals of at least 1 week
Usual maintenance dose	50–150 mg once daily
Maximum dose	200 mg per day
Duration	Minimum 6–12 months after symptom resolution. Gradual taper over 4–8 weeks when discontinuing.

Mandatory Clinical Notes:

When to prefer: Recommended first-line SSRI for panic disorder. Equally effective as paroxetine with better tolerability and easier discontinuation. [Evidence-based]
When NOT to use: Do not start at 50 mg — almost invariably worsens panic initially. Co-prescribe a short course of benzodiazepine (clonazepam 0.25–0.5 mg BD for 2–4 weeks) to cover the initial activation period if panic is severe.
NLEM India status: Not in NLEM 2022.
Time to response: 2–4 weeks for reduction in panic attack frequency. Full response in 6–8 weeks.
Treatment failure: No significant reduction in panic frequency after 8 weeks at ≥100 mg. Consider switching to venlafaxine or clomipramine.
Mandatory baseline: Same as MDD.
Specialist vs primary care: Can be initiated in primary care. Referral if treatment-resistant or comorbid agoraphobia not responding.
Indian guideline source: IPS Guidelines for Anxiety Disorders; API Textbook.
⚠️ Key safety warning: Initial jitteriness/activation syndrome — warn patient that anxiety may transiently worsen in first 1–2 weeks. This is not treatment failure.
Dose adjustment: Lower starting dose mandatory. Do not rush titration.

4. Post-Traumatic Stress Disorder (PTSD)

Parameter	Details
Starting dose	25 mg once daily
Titration	Increase to 50 mg after 1 week, then by 25–50 mg at intervals of at least 1 week
Usual maintenance dose	50–200 mg once daily
Maximum dose	200 mg per day
Duration	Minimum 12 months. Many patients require extended or indefinite treatment.

Mandatory Clinical Notes:

When to prefer: First-line pharmacotherapy for PTSD (along with paroxetine and venlafaxine). Sertraline has the strongest evidence base for PTSD among SSRIs. [Evidence-based]
When NOT to use: Monotherapy is inferior to trauma-focused CBT/EMDR. Combine with psychotherapy when available.
NLEM India status: Not in NLEM 2022.
Time to response: 4–6 weeks. Full benefit may take 8–12 weeks.
Treatment failure: Insufficient response after 8–12 weeks at adequate dose. Consider augmentation with prazosin (for nightmares), or switching to venlafaxine.
Mandatory baseline: Same as MDD plus trauma history documentation.
Specialist vs primary care: Specialist initiation recommended.
Indian guideline source: IPS Guidelines; NIMHANS treatment protocols.
Key safety warning: Suicidality monitoring. Insomnia and nightmares may persist — consider adjunctive prazosin.
Dose adjustment: Higher doses often needed (150–200 mg).

5. Social Anxiety Disorder (Social Phobia)

Parameter	Details
Starting dose	25 mg once daily
Titration	Increase to 50 mg after 1 week, then by 25–50 mg at weekly intervals
Usual maintenance dose	50–150 mg once daily
Maximum dose	200 mg per day
Duration	Minimum 6–12 months. Relapse common on discontinuation.

Mandatory Clinical Notes:

When to prefer: First-line SSRI for social anxiety disorder. [Evidence-based]
When NOT to use: Performance-only social anxiety may respond to PRN beta-blockers (propranolol) — sertraline unnecessary.
NLEM India status: Not in NLEM 2022.
Time to response: 4–8 weeks.
Treatment failure: No response after 8 weeks at ≥100 mg. Consider venlafaxine or augmentation.
Mandatory baseline: Same as MDD.
Specialist vs primary care: Can be initiated in primary care.
Indian guideline source: IPS Guidelines for Anxiety Disorders.
Key safety warning: Initial activation/jitteriness — same as panic disorder.
Dose adjustment: Start low, titrate gently.

6. Premenstrual Dysphoric Disorder (PMDD)

Dosing Strategy	Starting Dose	Titration	Usual Dose	Maximum Dose	Duration
Continuous dosing (throughout cycle)	50 mg once daily	Increase to 100 mg after one menstrual cycle if needed	50–100 mg/day	150 mg per day	At least 3–6 cycles to assess efficacy
Luteal phase dosing (14 days before expected menses until onset of menses)	50 mg once daily during luteal phase	Increase to 100 mg for next cycle if needed	50–100 mg/day	100 mg per day (luteal phase)	At least 3–6 cycles

Mandatory Clinical Notes:

When to prefer: First-line pharmacotherapy for PMDD when lifestyle measures insufficient. SSRIs are more effective than hormonal therapies for mood symptoms of PMDD. Sertraline has the most evidence among SSRIs for PMDD. [Evidence-based]
When NOT to use: Premenstrual syndrome (PMS) without significant mood/functional impairment does not require SSRI therapy.
NLEM India status: Not in NLEM 2022.
Time to response: Rapid — often within the first cycle of treatment (unlike MDD where 4–6 weeks needed). This rapid onset in PMDD is unique and may relate to a different mechanism.
Treatment failure: No improvement after 2–3 cycles at adequate dose. Consider switching to another SSRI or hormonal approaches (OCP, GnRH agonist).
Mandatory baseline: Clinical confirmation of PMDD using prospective daily symptom charting over ≥2 cycles (retrospective self-report is unreliable). Rule out underlying MDD or anxiety disorder.
Specialist vs primary care: Can be initiated by gynaecologist or primary care physician.
Indian guideline source: FOGSI guidelines on PMDD; API Textbook.
Key safety warning: Luteal phase dosing avoids continuous drug exposure and is preferred when feasible. ℹ️ When using luteal phase dosing, SSRI discontinuation symptoms generally do not occur because exposure is too brief to establish significant steady-state levels.
Dose adjustment: Lower doses typically sufficient compared to MDD.

Secondary Indications — Adults Only (Off-label, if any)

1. Premature Ejaculation — OFF-LABEL but accepted standard practice in India

Parameter	Details
Indication	Premature ejaculation (PE) — lifelong and acquired
Dosing strategy 1 (daily)	25–50 mg once daily, continuously
Titration	May increase to 100 mg/day if inadequate response after 4 weeks
Maximum dose	100 mg per day; 100 mg per dose
Dosing strategy 2 (on-demand)	50 mg taken 4–8 hours before anticipated intercourse
Duration	Daily: minimum 4–6 weeks before assessing efficacy. On-demand: PRN basis.
Specialist only	No — commonly initiated by urologists, andrologists, and general practitioners
Label status	OFF-LABEL but accepted standard practice in India. Dapoxetine (short-acting SSRI) is the only CDSCO-approved drug for PE in India. Sertraline is widely used as a daily-dosing alternative.
Evidence basis	Multiple RCTs demonstrating significant increase in intravaginal ejaculation latency time (IELT). Standard Indian urological and andrological practice. AIIMS Urology protocols include sertraline as option for PE.
Level of evidence	Strong — multiple RCTs and meta-analyses

ℹ️ Clinical Notes:

Daily dosing provides more consistent benefit than on-demand use. On-demand use is less effective than dapoxetine for as-needed strategy.
Dapoxetine (30–60 mg PRN) is preferred for on-demand use; sertraline is preferred when daily dosing is acceptable to the patient.
Delayed ejaculation (a common SSRI side effect) is the therapeutic mechanism — this should be explained to the patient.
Effect is lost within 1–2 weeks of discontinuation.

2. Generalised Anxiety Disorder (GAD) — OFF-LABEL

Parameter	Details
Indication	Generalised Anxiety Disorder
Starting dose	25–50 mg once daily
Titration	Increase by 25–50 mg at weekly intervals
Usual maintenance dose	50–150 mg once daily
Maximum dose	200 mg per day
Duration	Minimum 6–12 months
Specialist only	No
Label status	OFF-LABEL. Escitalopram, venlafaxine, and duloxetine have approved GAD indications; sertraline does not.
Evidence basis	Several RCTs support efficacy. Indian specialist practice commonly uses sertraline for GAD.
Level of evidence	Strong — RCTs available, though not as extensively studied as escitalopram/venlafaxine for this specific indication

3. Body Dysmorphic Disorder (BDD) — OFF-LABEL

Parameter	Details
Indication	Body Dysmorphic Disorder
Dose	50–200 mg once daily (higher doses often required, similar to OCD)
Duration	Long-term
Specialist only	Yes — Psychiatry
Label status	OFF-LABEL
Evidence basis	Case series and small RCTs. BDD is conceptualised within OCD spectrum.
Level of evidence	Moderate — limited RCT data, expert consensus

PAEDIATRIC DOSING (Specialist Only)

General Notes:

⚠️ FDA Black Box Warning equivalent — applicable in Indian practice: All SSRIs including sertraline carry an increased risk of suicidal thinking and behaviour in children and adolescents. Close monitoring is mandatory during initiation and dose changes.
Safety monitoring: Weekly face-to-face or telephone contact for first 4 weeks, then fortnightly for 4 weeks, then monthly. Assess for suicidality, agitation, irritability, self-harm.
Minimum age: 6 years for OCD (approved). Below 6 years — no established dosing; use only under specialist supervision.
Formulation suitability: Tablets are available in 25 mg and 50 mg strengths, suitable for paediatric dosing. No palatable liquid formulation is widely available in India, which limits use in very young children who cannot swallow tablets. Tablets can be split (scored) if needed.
Palatability: Tablets have a mild bitter taste if crushed. Oral concentrate (20 mg/mL) is preferred for dose flexibility but has limited availability in India.
Paediatric PK: Children aged 6–12 years have slightly higher weight-adjusted clearance compared to adolescents. Standard age-based dosing accounts for this.
Adolescent transition: ≥13 years or ≥40 kg: Use adolescent dosing (approaching adult doses). ≥18 years: Adult dosing applies.
Neonatal dosing: No neonatal dosing established. Not applicable.

Primary Indications — Paediatric (Approved / Standard in India)

1. Obsessive-Compulsive Disorder (OCD)

Age Group	Starting Dose	Titration	Usual Maintenance	Maximum Dose
6–12 years	25 mg once daily	Increase by 25 mg at intervals of at least 1 week	50–100 mg/day	200 mg/day
13–17 years	50 mg once daily	Increase by 50 mg at intervals of at least 1 week	100–200 mg/day	200 mg/day

Clinical Notes:

When to prefer: First-line SSRI for paediatric OCD. IAP guidelines and NIMHANS protocols include sertraline as a recommended pharmacological option.
When NOT to use: Mild OCD responding to CBT alone. Avoid in children with bipolar spectrum disorders without mood stabiliser.
NLEM India status: Not in NLEM 2022.
Time to response: 4–8 weeks. Full response may take 12 weeks. Ensure adequate trial duration before concluding non-response.
Treatment failure: <25% improvement in CY-BOCS after 12 weeks at maximum tolerated dose. Consider switching to fluvoxamine or adding low-dose risperidone (specialist only).
Mandatory baseline: Clinical assessment of OCD severity (CY-BOCS), suicidality assessment, weight, height.
Specialist initiation: Yes — Psychiatrist or child psychiatrist.
Indian guideline source: IAP Guidelines on Paediatric Mental Health; NIMHANS Clinical Practice Guidelines.
⚠️ Key safety warning: Suicidality monitoring — weekly for first 4 weeks. Behavioural activation (agitation, irritability, impulsivity) must be differentiated from suicidality.
Dose adjustment: Start low, titrate slowly. Maximum absolute dose is 200 mg regardless of weight.

Secondary Indications — Paediatric (Off-label, if any)

1. Major Depressive Disorder in Adolescents (≥12 years) — OFF-LABEL

Parameter	Details
Indication	MDD in adolescents aged 12–17 years
Starting dose	25 mg once daily
Titration	Increase to 50 mg after 1 week, then by 25–50 mg at weekly intervals
Usual dose	50–150 mg/day
Maximum	200 mg/day
Duration	Minimum 6 months after remission
Specialist only	Yes — Child/Adolescent Psychiatrist
Label status	OFF-LABEL. Fluoxetine is the only SSRI with robust evidence and regulatory support for adolescent MDD.
Evidence basis	TADS trial included sertraline data. Some positive RCTs but less consistent than fluoxetine. Indian specialist practice uses sertraline as second-line when fluoxetine is not tolerated or ineffective.
Level of evidence	Moderate — Adult RCTs with paediatric-specific data available but less robust than fluoxetine

ℹ️ Fluoxetine remains the preferred first-line SSRI for adolescent depression. Sertraline is a reasonable second choice.

2. Anxiety Disorders in Children and Adolescents (GAD, Separation Anxiety, Social Anxiety) — OFF-LABEL

Parameter	Details
Indication	Childhood anxiety disorders (≥6 years)
Starting dose	25 mg once daily
Titration	Increase by 25 mg at weekly intervals
Usual dose	50–150 mg/day
Maximum	200 mg/day
Specialist only	Yes
Label status	OFF-LABEL but accepted standard practice.
Evidence basis	CAMS trial (Child/Adolescent Multimodal Study) demonstrated efficacy of sertraline for childhood anxiety disorders. Standard practice in Indian paediatric psychiatry.
Level of evidence	Strong — Paediatric RCTs exist (CAMS trial)

MISSED DOSE / DELAYED DOSE GUIDANCE

Dosing frequency: Sertraline is taken once daily.

Scenario	Guidance
Missed dose (<12 hours late)	Take as soon as remembered. Then resume usual schedule.
Missed dose (>12 hours late)	Skip the missed dose. Take the next dose at the usual time. Never double the dose.
Delayed dose (1–6 hours late)	Clinically acceptable. Take immediately and resume usual schedule.
2–3 consecutive missed doses	Resume at the previous dose — re-titration is not necessary due to the long half-life of sertraline (~26 hours) and its active metabolite (~62–104 hours). Steady state is partially maintained.
>7 consecutive missed doses	⚠️ Consider restarting at a lower dose (25–50 mg) and re-titrating over 1–2 weeks. Abrupt resumption at the previous full dose is unlikely to cause harm but may provoke GI side effects (nausea).
Luteal phase dosing (PMDD)	If a dose is missed during the luteal phase, take as soon as remembered if within the luteal phase window. If the menses has started, discontinue and resume at the start of the next luteal phase.

SSRI Discontinuation Risk with Missed Doses:

Sertraline has a moderate risk of discontinuation syndrome (less than paroxetine or venlafaxine, more than fluoxetine).
After ≥4 weeks of continuous use, repeated missed doses can precipitate: dizziness, electric shock sensations (“brain zaps”), nausea, irritability, insomnia, vivid dreams.
If a patient reports discontinuation symptoms from missed doses, emphasise importance of regular dosing and consider switching to fluoxetine (longer half-life) or using a slower taper when stopping.

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

Sertraline is an oral-only medication. No parenteral formulations exist.

Oral Administration Notes

Parameter	Details
Tablets	Swallow whole with water. May be taken with or without food. Taking with food reduces initial nausea.
Crushing/splitting	Tablets can be split along score line if needed for dose titration (25 mg increments). Can be crushed if patient has difficulty swallowing — mix with small amount of water or soft food (applesauce). Taste may be bitter.
Timing of administration	Morning or evening — patient preference. If causing insomnia, take in the morning. If causing drowsiness, take in the evening.
Enteral tube compatibility	Tablets may be crushed and dispersed in water for administration via NG/PEG tube. Flush tube with 20–30 mL water before and after.
Oral concentrate (20 mg/mL) (limited availability in India)	Must be diluted before administration. Dilute prescribed dose in 120 mL (4 oz) of water, ginger ale, lemon-lime soda, lemonade, or orange juice ONLY. Do not mix with other liquids. Use immediately after dilution. ⚠️ Oral concentrate contains alcohol — contraindicated with disulfiram.

Storage

Condition	Guidance
Tablets	Store below 30°C, in a dry place, protected from moisture.
Oral concentrate	Store below 30°C. Replace cap tightly after each use.

Cold-chain guidance: Not applicable (not a cold-chain drug).

Multi-dose vial handling: Not applicable.

Weight-based dosing calculation example: Not applicable (sertraline is dosed by age group, not weight, in standard practice).

RENAL ADJUSTMENT

Sertraline is extensively hepatically metabolised with <0.2% excreted unchanged in urine. Renal impairment does not significantly alter pharmacokinetics.

eGFR (mL/min)	Dose Adjustment	Notes
>60	No adjustment required	—
30–60	No adjustment required	—
15–30	No adjustment required	Standard doses can be used. Monitor for adverse effects.
<15 (non-dialysis)	No adjustment required	Limited data in severe renal impairment. Use standard doses with monitoring.
Haemodialysis	No supplemental dose post-HD	Not significantly dialysed (98% protein bound, large Vd).
Peritoneal dialysis	No adjustment	—
CRRT	No adjustment	—

ARC (Augmented Renal Clearance): Not relevant — sertraline is not renally cleared.

eGFR formula used: Not applicable — no renal dose adjustment needed.

HEPATIC ADJUSTMENT

Sertraline undergoes extensive hepatic metabolism. Hepatic impairment significantly alters pharmacokinetics.

Severity	Dose Guidance
Mild (Child-Pugh A)	Start at 25 mg once daily. Titrate cautiously. Maximum 150 mg/day. Monitor for adverse effects.
Moderate (Child-Pugh B)	Start at 25 mg once daily. Titrate slowly (every 2–3 weeks). Reduce target dose by approximately 50%. Maximum 100 mg/day. AUC and half-life are significantly increased.
Severe (Child-Pugh C)	⛔ Avoid use. CDSCO product insert recommends against use in severe hepatic impairment. If essential, use only under specialist supervision at very low doses (25 mg every other day or 25 mg daily) with frequent LFT monitoring.

Hepatic metabolism is the primary elimination route — impairment significantly increases systemic exposure.
N-desmethylsertraline (active metabolite) accumulates in liver disease due to reduced metabolism.
Protein binding may be reduced in hypoalbuminaemia, increasing free drug fraction.

Concurrent hepatotoxin note: ⚠️ When combined with rifampicin, isoniazid, or pyrazinamide (anti-TB therapy — extremely common in India), monitor LFTs more frequently (baseline, then every 2 weeks for first 2 months). Rifampicin also induces sertraline metabolism (see Drug Interactions), compounding the complexity. When combined with valproate or methotrexate, additional LFT monitoring is warranted.

CONTRAINDICATIONS

Contraindication	Clinical Rationale
⛔ Known hypersensitivity to sertraline or any excipient	Risk of anaphylaxis, angioedema, severe dermatological reactions
⛔ Concurrent MAOI use (phenelzine, tranylcypromine, isocarboxazid, selegiline at anti-depressant doses, rasagiline)	Risk of fatal serotonin syndrome. 14-day washout required when switching between MAOI and sertraline (in either direction).
⛔ Concurrent linezolid (systemic) or IV methylene blue	Both have MAOI activity — serotonin syndrome risk
⛔ Concurrent pimozide	Increased pimozide levels (CYP2D6 inhibition) + additive QT prolongation — risk of torsades de pointes
⛔ Concurrent disulfiram (with oral concentrate formulation only)	Oral concentrate contains alcohol — disulfiram reaction. Not applicable to tablet formulation.

Allergy Cross-Reactivity:

Cross-reactivity between different SSRIs is rare but reported (case reports of patients allergic to one SSRI tolerating others). Cross-reactivity is idiosyncratic, not structure-based.
If a patient has had anaphylaxis or severe reaction to sertraline, avoid all SSRIs and use a different class (SNRI, bupropion, mirtazapine) unless allergist-supervised challenge is performed.

CAUTIONS

⚠️ High-Priority Cautions

Condition	Concern	Monitoring Required
Suicidality risk (age 18–24 years)	Increased risk of suicidal ideation/behaviour during initial treatment weeks	Weekly contact for first 4 weeks. Do not prescribe >2 weeks supply at a time. Involve family in monitoring.
Undiagnosed bipolar disorder	Risk of manic/hypomanic switch if SSRI used without mood stabiliser in unrecognised bipolar depression	Screen for bipolar features (family history, prior hypomania, irritability, rapid cycling) before starting. If manic switch occurs, discontinue SSRI and start mood stabiliser.
Hyponatraemia / SIADH risk	Can cause syndrome of inappropriate ADH secretion, leading to severe hyponatraemia. Risk increased in elderly, concurrent diuretics, low body weight.	Check serum sodium at baseline and at 2–4 weeks in at-risk patients. Monitor for confusion, drowsiness, headache, seizures.
Bleeding risk	SSRIs inhibit platelet serotonin uptake, impairing aggregation. Risk of GI bleeding, bruising, epistaxis. Risk amplified with concurrent anticoagulants, antiplatelets, or NSAIDs.	Review concurrent anticoagulant/NSAID use. Warn about unexplained bruising/bleeding. Consider PPI co-prescription if on concurrent NSAIDs.
Seizure disorder	SSRIs may lower seizure threshold. Risk is dose-dependent.	Use at lowest effective dose. Monitor seizure frequency.
Angle-closure glaucoma	Mydriatic effect of serotonergic drugs may precipitate acute angle-closure in predisposed patients.	Warn patients with narrow anterior chamber angles. Ophthalmology review if eye pain/visual disturbance occurs.
QT prolongation	Dose-dependent QTc prolongation, especially at doses >150 mg.	ECG at baseline in patients with cardiac risk factors. Avoid concurrent QT-prolonging drugs at higher sertraline doses.
Hepatic impairment	Significantly altered PK. See Hepatic Adjustment section.	LFTs at baseline and periodically.
Serotonin syndrome risk (concurrent serotonergic drugs)	Even with “moderate” interactions, the cumulative serotonergic load can precipitate serotonin syndrome.	Review all concurrent serotonergic drugs. Educate patient on warning signs.

Standard Cautions

Condition	Concern
Diabetes mellitus	May alter glycaemic control (both hypo- and hyperglycaemia reported). Monitor blood glucose in diabetic patients, especially during dose changes.
History of mania (treated/controlled bipolar disorder on mood stabiliser)	Lower threshold for manic switch even with mood stabiliser in place. Monitor closely.
Weight concerns	Initial weight loss may occur; long-term use may cause modest weight gain. Monitor weight periodically.
Sexual dysfunction	Very common. Inquire proactively as patients rarely volunteer this information.
Elderly patients on multiple medications	Polypharmacy increases drug interaction risk and adverse effect burden.
Concomitant ECT	May alter seizure threshold and ECT seizure duration. Coordinate with ECT team.

PREGNANCY

Parameter	Details
Overall safety statement	Sertraline is considered one of the preferred SSRIs for use during pregnancy when antidepressant treatment is necessary. Untreated maternal depression carries significant risks to both mother (suicide, self-neglect, poor prenatal care) and fetus/neonate (preterm birth, low birth weight, developmental effects). (Former US-FDA Category C.)
Teratogenicity window	First 8 weeks post-conception (major organogenesis). No confirmed structural teratogenicity at standard therapeutic doses. Some early studies suggested a small increased risk of cardiac septal defects, but larger studies and meta-analyses have not consistently confirmed this. Overall, the absolute risk increase is very small if any.
First trimester	No clearly established teratogenic risk. Among SSRIs, sertraline has relatively low placental transfer (placental transfer ratio ~0.3–0.6, one of the lowest among SSRIs).
Second trimester	Generally considered safe. Monitor maternal mood — clearance may increase requiring dose adjustment.
Third trimester	⚠️ Use in late pregnancy (especially last 4 weeks) is associated with Neonatal Adaptation Syndrome (NAS) in up to 30% of exposed neonates: irritability, constant crying, tremor, feeding difficulties, respiratory distress, jitteriness. Usually self-limiting (resolves in 1–4 days). Rarely requires NICU admission. ⚠️ Persistent Pulmonary Hypertension of the Newborn (PPHN): Rare (estimated 2–3 per 1,000 exposed vs 1–2 per 1,000 unexposed). Associated with SSRI use after 20 weeks.
Preferred alternatives	Sertraline IS a preferred SSRI during pregnancy due to lowest placental transfer and most safety data. Fluoxetine is an alternative but has higher placental transfer and longer neonatal washout.
When it may be used	When antidepressant treatment is necessary during pregnancy. Do not discontinue sertraline in a pregnant woman with moderate-to-severe depression without specialist guidance — relapse risk is 50–70% during pregnancy if antidepressant is stopped.
Monitoring — mother	Mood assessment at each antenatal visit. May need dose increase in second/third trimester due to increased clearance.
Monitoring — fetus/neonate	Routine antenatal monitoring. Neonatal observation for NAS for 48 hours after delivery. NICU notification if SSRI exposure in last trimester.
Pre-conception counselling	Discuss risks and benefits. If patient is well and on sertraline, generally recommend continuing rather than switching/stopping. No specific washout period required. Folic acid supplementation (standard 5 mg/day) recommended.
Contraception requirements	Not applicable — no mandatory contraception requirement.

Fertility Effects

Some evidence suggests SSRIs including sertraline may reversibly affect sperm motility and DNA fragmentation in males. Clinical significance uncertain. Fertility impairment has not been consistently demonstrated at standard doses.
Female fertility: No established significant effect on ovulation or fertility at standard doses. Some reports of cycle irregularity.
Washout before planned conception in males: Consider temporary discontinuation (if clinically feasible) if male partner has documented subfertility, but this is not a standard recommendation.

LACTATION

Parameter	Details
Compatible with breastfeeding	Yes — generally considered compatible. Sertraline is one of the preferred SSRIs for lactating mothers.
Drug levels in breast milk	Very low. RID (Relative Infant Dose): ~0.4–2.2% — well below the 10% threshold of concern. Sertraline and its metabolite are often undetectable in infant serum.
Preferred alternatives	None needed — sertraline IS the preferred SSRI for breastfeeding (along with paroxetine, which has similarly low milk transfer but higher discontinuation syndrome risk).
Monitoring in infant	Observe for: excessive drowsiness, poor feeding, irritability, poor weight gain. These are very rarely reported with sertraline.
Timing advice	No strict timing adjustment needed given very low milk transfer. If desired, take sertraline immediately after a breastfeed and before the longest inter-feed interval (e.g., at night after last feed).

Effect on milk production: No known suppressive or stimulatory effect on lactation. SSRIs do not generally affect prolactin levels sufficiently to alter milk production.

Temporary incompatibility: Not applicable — sertraline is compatible with breastfeeding at all times during therapy.

ELDERLY

Definition: ≥60 years (per Indian Census/National Programme for Health Care of the Elderly).

Parameter	Details
Recommended starting dose	25 mg once daily
Titration	Increase by 25 mg every 2 weeks (slower than in younger adults where weekly titration is acceptable)
Usual maintenance dose	50–100 mg once daily
Maximum dose	150 mg/day recommended ceiling in elderly (200 mg only if specialist-supervised)

Extra Risks Specific to Elderly:

Risk	Details
Hyponatraemia / SIADH	⚠️ Most important risk in elderly. Occurs in 5–12% of elderly SSRI users (higher than younger adults). Risk amplified by concurrent diuretics (thiazides > loop), ACE inhibitors, low body weight, female sex. Can present as confusion, falls, seizures. Check sodium at baseline, 2 weeks, and 4 weeks.
Falls	SSRIs increase fall risk in elderly through: dizziness, postural hypotension, hyponatraemia, gait impairment. Risk comparable to benzodiazepines.
GI bleeding	Higher baseline GI bleeding risk in elderly compounded by SSRI platelet effects. Risk significantly increased if on concurrent NSAIDs or aspirin. Co-prescribe PPI if concurrent NSAID use.
QT prolongation	Elderly more susceptible at standard doses. ECG at baseline recommended.
Bone loss	Long-term SSRI use associated with reduced BMD and increased fracture risk in elderly. Consider bone health monitoring.
Postural hypotension	Less common than with TCAs but can occur. Measure standing BP.
Drug interactions	Polypharmacy is the norm in elderly Indian patients. Review all medications for serotonergic, bleeding, and CYP interactions.

Beers Criteria / STOPP-START:

SSRIs are NOT on the Beers “avoid” list but are listed under “use with caution” due to hyponatraemia and fall risk.
STOPP: Avoid SSRI + NSAID without PPI cover.
START: Consider antidepressant (SSRI) for moderate-severe depression in elderly — undertreatment is common.

Common Indian clinical scenario: Elderly patient (65 years) with depression, hypertension on amlodipine + hydrochlorothiazide, type 2 diabetes on metformin, and knee osteoarthritis on ibuprofen PRN.

⚠️ Hydrochlorothiazide + sertraline: high hyponatraemia risk → check sodium.
Ibuprofen + sertraline: GI bleeding risk → co-prescribe PPI; consider switching to paracetamol.
Start sertraline at 25 mg, monitor sodium at 2 weeks.

Anticholinergic burden: Sertraline has no significant anticholinergic properties (ACB score = 0). This is an advantage over TCAs and paroxetine (which has mild anticholinergic activity) in elderly patients already on anticholinergic medications.

Deprescribing guidance:

Consider deprescribing if: depression in sustained remission for ≥12 months (first episode) or ≥2 years (recurrent episodes), patient preference, intolerable adverse effects.
Tapering schedule: Reduce by 25 mg every 2–4 weeks. Minimum taper duration 4–8 weeks. Final step from 25 mg may be 25 mg every other day for 1–2 weeks, then stop.
Expected withdrawal effects: Discontinuation syndrome — dizziness, electric shock sensations (“brain zaps”), nausea, irritability, vivid dreams, insomnia. Usually mild and self-limiting (1–3 weeks). If severe, slow taper further or temporarily reinstate at last effective dose.
Monitor for relapse: Depression recurrence risk is highest in first 6 months after stopping. Follow up monthly for 6 months.

MAJOR DRUG INTERACTIONS

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
⛔ MAOIs (phenelzine, tranylcypromine, selegiline, rasagiline, moclobemide)	Combined serotonergic excess — inhibition of serotonin metabolism + reuptake blockade	Fatal serotonin syndrome: hyperthermia, rigidity, autonomic instability, coma, death	Acute — within hours of co-ingestion	CONTRAINDICATED. 14-day washout required in both directions. Moclobemide (reversible MAOI): 2-day washout from moclobemide before starting sertraline.
⛔ Linezolid (systemic)	Linezolid has non-selective MAOI activity	Serotonin syndrome	Acute	CONTRAINDICATED. If linezolid is essential, stop sertraline ≥2 days before and do not restart until 24 hours after last linezolid dose. Very relevant in India given high TB/MDR-TB burden and linezolid use.
⛔ IV Methylene blue	MAOI activity	Serotonin syndrome	Acute	CONTRAINDICATED. Topical/low-dose methylene blue for surgical marking is NOT a concern.
⛔ Pimozide	CYP2D6 inhibition by sertraline increases pimozide levels + additive QT prolongation	Torsades de pointes, cardiac arrest	Acute to gradual	CONTRAINDICATED.
⚠️ Thioridazine	CYP2D6 inhibition increases thioridazine levels	QT prolongation, torsades de pointes	Gradual (days)	Avoid. Do not start thioridazine within 14 days of sertraline cessation.
⚠️ Other QT-prolonging drugs at high doses (haloperidol, ondansetron, erythromycin, fluoroquinolones, domperidone, citalopram)	Additive QT prolongation	Torsades de pointes	Gradual	Avoid combination at high doses. ECG monitoring if combination unavoidable. Domperidone is very commonly co-prescribed in India as anti-emetic — use lowest effective dose and limit duration.
⚠️ St. John’s Wort (Hypericum perforatum)	Serotonin reuptake inhibition by St. John’s Wort + CYP3A4/CYP2C19 induction reducing sertraline levels	Serotonin syndrome risk AND subtherapeutic sertraline levels	Acute (serotonin syndrome) + Gradual (enzyme induction)	Avoid. Commonly used herbal remedy in India. Counsel patients to stop. Traditional medicine interaction.

MODERATE DRUG INTERACTIONS

Interacting Drug/Substance	Mechanism	Clinical Effect	Monitoring/Action
Warfarin	Sertraline inhibits CYP2C9 (weak) + SSRI-mediated platelet impairment	Increased INR, increased bleeding risk. INR may rise by 0.5–1.5 units.	Check INR within 1 week of starting sertraline. Recheck at 2 and 4 weeks. May need warfarin dose reduction of 10–20%. Common combination in elderly Indian patients with AF.
NSAIDs (ibuprofen, diclofenac, naproxen) and Aspirin	Additive inhibition of platelet function + GI mucosal effects	GI bleeding risk increased 2–3 fold vs either drug alone	Co-prescribe PPI (pantoprazole 40 mg or rabeprazole 20 mg). Very common in Indian practice — NSAIDs are widely available OTC. Counsel patients.
Tramadol	Serotonin reuptake inhibition by tramadol + CYP2D6 inhibition by sertraline increasing tramadol levels	Serotonin syndrome risk + reduced seizure threshold	⚠️ Use with caution. Prefer non-serotonergic analgesics. Monitor for myoclonus, agitation, hyperthermia.
Triptans (sumatriptan, rizatriptan, zolmitriptan)	Additive serotonergic effects	Serotonin syndrome (rare but reported)	Can be used together with monitoring. Risk is low at standard doses. Counsel patient on serotonin syndrome symptoms.
Lithium	Additive serotonergic effects	Serotonin syndrome risk. May also affect lithium levels.	Monitor lithium levels. Watch for serotonin syndrome. Commonly co-prescribed in treatment-resistant depression — generally safe with monitoring.
Rifampicin	Potent inducer of CYP3A4, CYP2C19, CYP2B6	⚠️ Can reduce sertraline plasma levels by up to 50% — risk of antidepressant non-response	Increase sertraline dose by 50–100% during concurrent rifampicin therapy. Monitor mood closely. Very common scenario in India given TB burden. Rifampicin effect develops over 1–2 weeks and resolves 1–2 weeks after stopping.
Carbamazepine / Phenytoin	CYP enzyme induction	Reduced sertraline levels	May need dose increase. Monitor mood response.
CYP2D6 substrates (amitriptyline, nortriptyline, haloperidol, risperidone, codeine, metoprolol)	Sertraline inhibits CYP2D6 (moderate)	Increased levels of co-prescribed CYP2D6 substrates. Risk of TCA toxicity, antipsychotic ADRs, beta-blocker ADRs. Reduced codeine → morphine conversion (reduced analgesic efficacy).	Reduce dose of CYP2D6 substrate if clinically indicated. Monitor for toxicity. Sertraline + amitriptyline: monitor TCA levels.
Cimetidine	Inhibits multiple CYP enzymes	Increased sertraline levels (~50% increase in AUC)	Use alternative H2 blocker (ranitidine/famotidine) or PPI. If cimetidine necessary, monitor for sertraline ADRs.
Alcohol	Additive CNS depression	Increased sedation, impaired psychomotor function, worsened depression	Advise patients to avoid or minimise alcohol consumption.
Diuretics (thiazides > loop)	Independent SIADH risk from both sertraline and diuretics	Additive hyponatraemia risk	Monitor serum sodium at 2 and 4 weeks after starting sertraline in patients on diuretics. Very common combination in elderly Indian patients.
Grapefruit juice	CYP3A4 inhibition	Minor increase in sertraline levels (sertraline is metabolised by multiple CYPs, so effect is diluted)	Routine avoidance not necessary. Large quantities (>1 L/day) may be clinically relevant.
Ashwagandha (Withania somnifera)	Theoretical potentiation of serotonergic/GABAergic effects	Theoretical increased sedation and serotonergic effects. No robust clinical data.	Counsel patients using Ashwagandha supplements to inform prescriber. Data limited. Traditional medicine interaction.
Brahmi (Bacopa monnieri)	Potential additive serotonergic effects (Bacopa may enhance serotonin signalling)	Theoretical serotonin syndrome risk at high supplemental doses.	Data limited. Counsel patients. Traditional medicine interaction.

COMMON ADVERSE EFFECTS

Frequency	System	Adverse Effect	Notes
Very common (≥10%)	GI	Nausea	Most common ADR (~25%). Usually transient — resolves in 1–2 weeks. Taking with food reduces severity.
Very common (≥10%)	GI	Diarrhoea / loose stools	~15–20%. Often transient. Sertraline has higher diarrhoea rates than other SSRIs.
Very common (≥10%)	CNS	Headache	~20%. Transient.
Very common (≥10%)	Sexual	Sexual dysfunction (delayed ejaculation, decreased libido, anorgasmia)	~15–30% (likely underreported). NOT transient — persists with continued use. Dose-dependent — worse at >100 mg.
Common (1–10%)	CNS	Insomnia	~10%. If problematic, switch dosing to morning or add short-term low-dose trazodone/melatonin.
Common (1–10%)	CNS	Somnolence / drowsiness	~10%. Paradoxically, some patients experience sedation. If so, take at bedtime.
Common (1–10%)	CNS	Dizziness	~5%.
Common (1–10%)	CNS	Tremor	~5%. Fine tremor of hands. Dose-dependent — more common at >100 mg.
Common (1–10%)	GI	Dry mouth	~5–10%.
Common (1–10%)	Autonomic	Increased sweating / hyperhidrosis	~5–8%. May persist.
Common (1–10%)	Metabolic	Weight change	Initial slight weight loss common. Long-term (>6 months): modest weight gain (1–3 kg) possible. Sertraline is more weight-neutral than paroxetine or mirtazapine.
Common (1–10%)	CNS	Fatigue	~5%.
Common (1–10%)	GI	Dyspepsia, abdominal pain	~5%.
Common (1–10%)	CNS	Agitation / nervousness	~5%. Especially in first 1–2 weeks (“activation syndrome”). More common in anxiety/panic disorders.

SERIOUS ADVERSE EFFECTS

Adverse Effect	Frequency	Details
⚠️ Serotonin syndrome	Rare (<1 in 1,000 as monotherapy; higher with drug combinations)	Presents with: hyperthermia, rigidity, myoclonus, agitation, autonomic instability, altered mental status, diarrhoea. Hunter Serotonin Toxicity Criteria for diagnosis. Requires immediate discontinuation of ALL serotonergic drugs. Antidote: Cyproheptadine 12 mg orally initially, then 4 mg every 2 hours until response (max 32 mg/day). Available in India — widely available at all levels of healthcare. Severe cases: ICU admission, neuromuscular paralysis, intubation.
⚠️ Suicidal ideation/behaviour	Uncommon — estimated 2–4% in under-25 age group vs 1–2% on placebo	Mainly in first 4 weeks of treatment. Not an adverse drug reaction in the pharmacological sense — may represent initial activation before antidepressant effect manifests. Close monitoring essential. No specific antidote — supportive/psychiatric management.
⚠️ Hyponatraemia / SIADH	Uncommon (~5% in elderly; <1% in younger adults)	Can cause seizures, confusion, falls, coma. Serum Na⁺ <130 mEq/L is clinically significant. <120 mEq/L is medical emergency. Management: discontinue sertraline, fluid restriction, specialist review. Severe cases may need hypertonic saline.
QT prolongation / Torsades de pointes	Very rare	Dose-dependent. Mainly at doses >150 mg or with concurrent QT-prolonging drugs. ECG monitoring at higher doses.
Abnormal bleeding (GI haemorrhage, epistaxis, ecchymosis, intracranial haemorrhage)	Uncommon	Risk increased 2–3 fold with concurrent NSAIDs/anticoagulants. GI bleeding may present as melaena or haematemesis.
Seizures	Very rare (<0.1%)	SSRIs may lower seizure threshold, though risk is lower than with TCAs or bupropion.
Mania / hypomania	Uncommon (~1–2% in unscreened patients)	Higher in undiagnosed bipolar disorder. Requires SSRI discontinuation and mood stabiliser initiation.
Hepatotoxicity	Very rare (case reports)	Cholestatic or mixed pattern hepatitis. Monitor LFTs if symptoms (jaundice, dark urine, RUQ pain) develop. Discontinue if LFTs >3× ULN with symptoms.
Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis	Extremely rare (<1 in 100,000)	Requires immediate discontinuation and hospitalisation. Early signs: widespread rash, mucosal involvement, fever, target lesions.
Angle-closure glaucoma	Rare	Acute eye pain, visual disturbance, haloes. Ophthalmology emergency.
SSRI Discontinuation Syndrome (on abrupt cessation)	Common (~20–30% on abrupt stop)	Not a “side effect” during use but on stopping. Dizziness, “brain zaps,” nausea, irritability, vivid dreams, paraesthesia. Usually self-limiting (1–3 weeks). Prevented by gradual taper.

⚠️ PvPI Reporting: Report ALL serious adverse effects to the nearest ADR Monitoring Centre under PvPI (Pharmacovigilance Programme of India) or via the ADR reporting form on the CDSCO website.

CDSCO safety alerts / Black box equivalent: CDSCO product inserts carry warnings about suicidality risk in children, adolescents, and young adults. No formal “black box” system exists in India, but this warning is equivalent to the US FDA black box warning.

MONITORING REQUIREMENTS

Baseline (Before Starting)

Parameter	Priority	Details
Mood assessment (PHQ-9 or clinical equivalent)	MANDATORY	Document baseline severity. Essential for tracking response.
Suicidality risk assessment	MANDATORY	Structured assessment. Determine if safe for outpatient management.
Weight	MANDATORY	Baseline for tracking changes.
Blood pressure	MANDATORY	Rule out hypertension; baseline for orthostatic effects monitoring.
Serum sodium	RECOMMENDED	Especially in: elderly ≥60 years, patients on diuretics, patients with low body weight, women.
Liver function tests	RECOMMENDED	Especially if hepatic risk factors (alcohol, concurrent hepatotoxins, known liver disease).
Full blood count	OPTIONAL	Baseline reference.
ECG	OPTIONAL	Recommended if: age >60, cardiac disease, family history of sudden cardiac death, concurrent QT-prolonging drugs, or if dose will exceed 150 mg.
Serum creatinine / eGFR	OPTIONAL	Not needed for dose adjustment but useful baseline in elderly.

Resource-limited surrogates: If PHQ-9 forms are not available, a structured clinical interview assessing core depressive symptoms (mood, sleep, appetite, energy, concentration, suicidality) is adequate. If serum sodium cannot be checked, monitor for clinical signs: confusion, drowsiness, headache, nausea, seizures — particularly in elderly patients on diuretics.

After Initiation / Dose Change

Parameter	Timing
Suicidality assessment	Weekly for first 4 weeks (especially age <25), then fortnightly for 4 weeks, then monthly
Mood assessment (PHQ-9)	At 2 weeks, 4 weeks, 6 weeks, 8 weeks
Serum sodium	At 2 weeks and 4 weeks if elderly or on diuretics
Weight	At 4 weeks and 12 weeks
LFTs	At 4–8 weeks if on concurrent hepatotoxins
Sexual function inquiry	At 4 weeks (proactively ask — patients rarely volunteer)

Long-Term / Maintenance

Parameter	Frequency
Mood assessment	Every 3 months (stable patient); more frequently if clinically indicated
Weight	Every 3–6 months
Serum sodium	Every 6–12 months in at-risk patients
LFTs	Annually if on long-term therapy; more frequently with concurrent hepatotoxins
Sexual function	Annually (minimum); proactively inquire
Bone health (DEXA scan)	Consider after >5 years of SSRI use in elderly, especially postmenopausal women
Blood pressure	Annually

Therapeutic Drug Monitoring (TDM)

Not applicable. Sertraline does not require routine TDM. Plasma level monitoring may be useful in:

Suspected non-adherence
Treatment-resistant cases (to confirm adequate levels)
Drug interaction assessment (especially with rifampicin)
Hepatic impairment (to avoid toxicity)

Therapeutic range (reference): 10–150 ng/mL (combined sertraline + N-desmethylsertraline). Availability of sertraline TDM in India is limited to select tertiary centres.

When to Stop Monitoring

Suicidality monitoring can be reduced to routine clinical visits once stable for >3 months and age >25 years.
Sodium monitoring can be stopped after 3 months if stable and no risk factors.
Ongoing periodic mood assessment remains essential throughout treatment.

PATIENT COUNSELLING

(Ready reference for the prescribing clinician to use during patient communication)

What this medicine is for:
“This medicine helps improve your mood, reduce worry and anxiety, and help you feel more like yourself. It works by correcting a chemical imbalance in the brain.”

How to take it:

“Take one tablet once a day, with a glass of water.”
“You can take it with food or without food — but taking it with food may reduce any stomach upset.”
“Take it at the same time every day. Choose either morning or evening — whichever works better for you.”
“If it makes you sleepy, take it at bedtime. If it keeps you awake, take it in the morning.”
“Swallow the tablet whole. If you have difficulty swallowing, it can be split or crushed.”

What to do if you miss a dose:
“If you forget to take your tablet, take it as soon as you remember. But if it is almost bedtime (or almost time for your next dose), skip the missed one and take the next dose at the usual time. Never take two tablets at once to make up.”

Common side effects to expect:
"In the first 1–2 weeks, you may feel:

Nausea or loose motions — this usually goes away on its own. Taking the medicine with food helps.
Headache — this is common and settles within a few days.
Mild trouble sleeping or feeling sleepy — will improve as your body adjusts.
Some people feel slightly more anxious or restless in the first week — this is temporary and does not mean the medicine is not working."

Warning signs to report immediately:
"Come to the doctor or hospital immediately if:

You feel more depressed, or have thoughts of harming yourself or ending your life — especially in the first few weeks
You develop a rash, especially if it involves your mouth, eyes, or is widespread
You feel very confused, very drowsy, or have a seizure (fit)
You have unusual bleeding — from gums, nose, or black stools
You develop high fever, stiff muscles, fast heartbeat, and feel very agitated — these could be signs of a rare but serious reaction"

Things to avoid:

“Avoid alcohol while taking this medicine — it can increase drowsiness and worsen your mood.”
“Do not take any herbal supplements (especially St. John’s Wort, Ashwagandha in supplement form, or Brahmi supplements) without telling your doctor.”
“Avoid taking painkillers like ibuprofen or diclofenac regularly without asking your doctor — they can increase the risk of stomach bleeding with this medicine.”

Storage:
“Keep in a cool, dry place below 30°C. Keep away from moisture. Store out of reach of children.”

Duration:
“⚠️ This medicine works slowly — you may not feel better for 2–4 weeks. Do not stop taking it because you don’t feel better immediately. Your doctor will tell you how long to continue. Most people need to take it for at least 6 months, and some people need it for much longer. Never stop this medicine suddenly — always reduce the dose slowly under your doctor’s guidance. Stopping suddenly can cause dizziness, nausea, and electric shock-like feelings.”

Follow-up:
“Come for a check-up as advised — usually every 1–2 weeks at first, then monthly. Your doctor may order blood tests (including a test for sodium levels) especially if you are elderly or on water tablets (diuretics).”

Common Patient Questions

“Can I take this with my other medicines?” — “Tell your doctor about ALL other medicines you take, including pain medicines, blood thinners, TB medicines, and any herbal or Ayurvedic preparations. Some combinations need monitoring.”
“Can I take this during fasting (Ramadan/Navratri)?” — “Yes, this is a once-daily medicine. You can take it at suhoor/sehri (pre-dawn meal) or iftar (evening meal). During Navratri, take it with your evening meal. It can be taken with or without food.”
“Will this affect my ability to drive or work?” — “Some people feel dizzy or drowsy, especially in the first few days. Avoid driving or operating heavy machinery until you know how the medicine affects you.”
“Is this medicine habit-forming?” — “No, this medicine is not addictive. However, stopping it suddenly after long use can cause withdrawal symptoms (dizziness, nausea, electric shock feelings). That is why we reduce the dose slowly when stopping — this is not the same as addiction.”
“Can I stop once I feel better?” — “No — do not stop on your own. Feeling better means the medicine is working. Stopping too early increases the chance of your symptoms returning. Your doctor will guide you on when and how to stop safely.”
“Will this affect my sex life?” — “Some people notice reduced interest in sex, difficulty reaching orgasm, or delayed ejaculation. This is a common side effect. If it bothers you, tell your doctor — the dose can sometimes be adjusted, or a different medicine can be tried.”

Caregiver/Family Counselling

(For patients who are severely depressed, elderly with cognitive impairment, or adolescents)

"Counsel the caregiver/family member on:

Ensure the patient takes the medicine every day at the same time
Watch for warning signs of worsening mood or suicidal thoughts, especially in the first 4 weeks
Do not leave large supplies of medicine accessible to a patient with suicidal risk
Report any sudden change in behaviour — increased agitation, talking about death, unusual calmness after severe depression, giving away possessions
Ensure the patient attends all follow-up appointments
Encourage the patient not to stop the medicine without medical advice"

India-Specific Adherence Support

Cost: “If cost is a concern, generic sertraline is available at much lower prices than branded versions. Ask your doctor to prescribe by generic name. Sertraline 50 mg costs approximately ₹3–10 per tablet for generic brands.”
Stigma: “Taking medicine for your mood does not mean you are ‘mad’ or ‘weak.’ Depression is a medical illness, just like diabetes or blood pressure. This medicine helps correct a chemical imbalance in your brain.”
Hot climate storage: “In Indian summers, store the medicine in the coolest part of the house (not in direct sunlight, not in the kitchen). Do not store in the bathroom. A dry bedroom cupboard is ideal.”

BRANDS AVAILABLE IN INDIA

Jan Aushadhi / PMBJP: Data limited — sertraline availability through Jan Aushadhi stores is not confirmed. If available, it would be the most affordable option.

Brand Name	Manufacturer	Key Strengths	Availability
Daxid	Pfizer (Viatris)	25 mg, 50 mg, 100 mg	Widely available — originator brand in India
Serlift	Torrent Pharmaceuticals	25 mg, 50 mg, 100 mg	Widely available
Serta	Intas Pharmaceuticals	25 mg, 50 mg, 100 mg	Widely available
Zosert	Sun Pharmaceutical	25 mg, 50 mg, 100 mg	Widely available
Serenata	Macleods Pharmaceuticals	25 mg, 50 mg, 100 mg	Widely available
Sertraline (generic)	Multiple generic manufacturers	25 mg, 50 mg, 100 mg	Widely available

Commonly Prescribed FDCs:

FDC	Brand Examples	Manufacturer	Availability
Sertraline + Clonazepam	Serta Plus, Serlift CZ	Intas, Torrent	Widely available

ℹ️ The Sertraline + Clonazepam FDC is widely prescribed in India for initial management of depression/anxiety with prominent anxiety. However, rational prescribing guidelines recommend limiting benzodiazepine to 2–4 weeks and then discontinuing the benzodiazepine component.

CDSCO NSQ alerts: No major Not of Standard Quality (NSQ) alerts or product recalls for major sertraline brands identified at the time of this entry. Prescribers should verify current CDSCO alerts periodically.

PRICE RANGE (INR)

Prices as of June 2025. Verify current prices on NPPA/1mg/PharmEasy/Jan Aushadhi price lists as prices may change.

Formulation	Per-Strip Price (10 tablets)	Per-Tablet Price	NPPA Controlled
25 mg tablets (branded)	₹30–80	₹3–8	Not NPPA controlled (not in NLEM 2022)
25 mg tablets (generic)	₹15–30	₹1.5–3	—
50 mg tablets (branded)	₹50–130	₹5–13	Not NPPA controlled
50 mg tablets (generic)	₹25–50	₹2.5–5	—
100 mg tablets (branded)	₹80–200	₹8–20	Not NPPA controlled
100 mg tablets (generic)	₹40–80	₹4–8	—

Estimated Monthly Cost at Usual Maintenance Dose:

Dose	Branded (approx.)	Generic (approx.)
50 mg/day	₹150–390/month	₹75–150/month
100 mg/day	₹240–600/month	₹120–240/month
150 mg/day	₹320–800/month	₹160–320/month

ℹ️ Sertraline is significantly more affordable than escitalopram (at equivalent therapeutic doses) and much cheaper than branded SNRIs (venlafaxine, duloxetine branded formulations). Generic sertraline at 50 mg/day costs approximately ₹2.5–5/day — among the most cost-effective antidepressants available in India.

PMBJP (Jan Aushadhi): Availability not confirmed. If available, expected price would be 50–70% lower than branded.

CLINICAL PEARLS

💡 Sertraline is the “workhorse” SSRI. [Evidence-based] It has the broadest approved indication range among SSRIs (MDD, OCD, Panic Disorder, PTSD, Social Anxiety, PMDD), a favourable drug interaction profile (lower CYP inhibition than fluoxetine or paroxetine), and proven cardiac safety (SADHART trial). If choosing a single SSRI to master, sertraline is an excellent choice.
💡 Start low in panic disorder — or you’ll worsen panic. [Evidence-based] Always start at 25 mg (not 50 mg) in panic disorder and social anxiety disorder. Initial jitteriness/activation syndrome peaks in days 3–7 and can cause patients to abandon treatment. Consider short-term benzodiazepine cover (clonazepam 0.25 mg BD for 2–3 weeks) during initiation.
💡 Rifampicin slashes sertraline levels. [Evidence-based] India’s TB burden means many depressed patients are on ATT. Rifampicin can reduce sertraline levels by 50% through CYP induction. If a patient on sertraline starts ATT and mood worsens, consider increasing sertraline dose by 50–100% rather than adding another antidepressant. Readjust downward when rifampicin stops.
💡 Check sodium in every elderly patient starting sertraline. [Practice-based] Hyponatraemia from SIADH is the most dangerous SSRI adverse effect in the elderly and is frequently missed until the patient presents with falls, confusion, or seizures. Check sodium at baseline, 2 weeks, and 4 weeks. Risk is highest when combined with thiazide diuretics — an extremely common co-prescription in elderly Indian patients with hypertension.
💡 Myth: “Antidepressants are addictive.” Fact: SSRIs including sertraline are NOT addictive. They do not produce euphoria, craving, dose escalation, or drug-seeking behaviour. The discontinuation syndrome (dizziness, brain zaps, nausea) on abrupt stopping is a pharmacological withdrawal effect (similar to abrupt beta-blocker cessation) and is NOT the same as addiction. Educating patients and families on this distinction is critical for treatment adherence in India, where mental health medication stigma remains a major barrier. [Practice-based]
💡 For premature ejaculation, sertraline is a cost-effective daily option. [Evidence-based] While dapoxetine is approved for on-demand PE treatment, it costs ₹30–60 per dose. Daily sertraline 50 mg at ₹3–5/day provides consistent IELT improvement and is preferred when regular sexual activity is anticipated. Counsel that effect takes 1–2 weeks to build and is lost within days of stopping.

VERSION

RxIndia v0.2 — 28 Jun 2025

REFERENCES

The following sources were consulted in preparing this monograph:

CDSCO Product Insert — Daxid (sertraline hydrochloride), Pfizer Ltd / Viatris, Indian product insert (most recent available revision).
CDSCO Product Insert — Serlift (sertraline hydrochloride), Torrent Pharmaceuticals, Indian product insert.
Indian Pharmacopoeia 2022 — Sertraline Hydrochloride monograph.
NLEM India 2022 — Reviewed for inclusion status. Sertraline is not listed; Fluoxetine (20 mg) is the SSRI included.
API Textbook of Medicine, 11th Edition — Chapter on Psychiatric Disorders: Depression, Anxiety Disorders, OCD.
Indian Psychiatric Society (IPS) Clinical Practice Guidelines for Management of Depression, 2017.
Indian Psychiatric Society (IPS) Clinical Practice Guidelines for Anxiety Disorders.
NIMHANS Clinical Practice Guidelines — OCD, Depression, Childhood Anxiety Disorders.
IAP (Indian Academy of Pediatrics) Guidelines — Paediatric Mental Health.
FOGSI Guidelines — Premenstrual Dysphoric Disorder management.
Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition — Chapter 15: Drug Therapy of Depression and Anxiety Disorders. Pharmacokinetics, mechanism of action, drug interactions.
Harrison’s Principles of Internal Medicine, 21st Edition — Chapter on Psychiatric Disorders.
Glassman AH, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina (SADHART trial). JAMA 2002;288(6):701–709. — Cardiac safety evidence (cited for Clinical Pearl).
Walkup JT, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety (CAMS trial). N Engl J Med 2008;359(26):2753–2766. — Paediatric anxiety off-label evidence.
McMahon CG, et al. Efficacy of SSRIs for premature ejaculation: meta-analysis. J Sex Med 2011. — Off-label PE evidence.
CDSCO FDC Gazette Notifications — Reviewed for banned sertraline-containing FDCs (none identified).

Anti-depressants

Sub-classifications

Cumulative Drug Index

Quick Links